Recently developed tryptase and PAR-2 antagonist compounds have been shown to inhibit the tryptase- and PAR-2-induced tissue responses [41,42], representing a novel therapeutic approach for preventing and treating ventilator- and ARDS-induced pulmonary fibrosis. Here, F2RL1 is linked to pulmonary fibrosis.